Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2005 3
2006 2
2007 1
2008 2
2010 4
2011 7
2012 9
2013 5
2014 4
2015 6
2016 4
2017 4
2018 6
2019 4
2020 15
2021 15
2022 18
2023 12
2024 26
2025 18
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hong yu yuan (14 results)?
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.
Hong RX, Xu F, Xia W, Teng YE, Ouyang QC, Zheng QF, Yuan ZY, Chen DS, Jiang KK, Lin Y, Dai Z, Liu XL, Chen QJ, Wu XH, Shi YX, Huang JJ, An X, Xue C, Bi XW, Chen MT, Li H, Yao HR, Zou GR, Huang H, Zhang JM, Wang SS. Hong RX, et al. J Clin Oncol. 2025 Apr 10;43(11):1314-1324. doi: 10.1200/JCO.24.00938. Epub 2025 Jan 2. J Clin Oncol. 2025. PMID: 39746176 Free PMC article. Clinical Trial.
The features of male breast cancer in China: A real-world study.
Gao Y, Zhang M, Sun G, Ma L, Nie J, Yuan Z, Liu Z, Cao Y, Li J, Liu Q, Ye S, Chen B, Song Y, Wang K, Ren Y, Ye G, Xu L, Liu S, Chen Q, Li W, Chen X, Fu P, Wei W, Guo B, Wang H, Cai Z, Du C, Wu Z, Zha X, Huang H, Xu J, Zhang C, Shi Y, Liu T, Liu S, Jiang Z, Lin Y. Gao Y, et al. Among authors: yuan z. Breast. 2024 Aug;76:103762. doi: 10.1016/j.breast.2024.103762. Epub 2024 Jun 22. Breast. 2024. PMID: 38924994 Free PMC article.
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.
Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY. Yuan J, et al. Lancet Oncol. 2025 Dec;26(12):1575-1583. doi: 10.1016/S1470-2045(25)00545-5. Lancet Oncol. 2025. PMID: 41308674 Clinical Trial.
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.
Wu W, Yang Y, Chen H, Lu Y, Zeng Y, Zhao J, Du C, Lin Y, Peng P, Huang M, Zhang Y, Ouyang Q, Ding L, Cheng Z, Wen Y, Wu Z, Ye J, Ling L, Wang K, Lu Y, Zou G, Zhong J, Wang H, Lin D, Zeng D, Yao C, Chen Q, Zou L, Wang S, Yu Y, Yuan Z, Wang Y, Yao H. Wu W, et al. Among authors: yuan z. Signal Transduct Target Ther. 2026 May 22;11(1):191. doi: 10.1038/s41392-026-02720-6. Signal Transduct Target Ther. 2026. PMID: 42168151 Free PMC article. Clinical Trial.
162 results